A citation-based method for searching scientific literature

Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, René DePont Christensen, Whitney Graybill, Mansoor R Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, Kris Jardon, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley F Haggerty, Maria J Rubio-Pérez, Mark S Shahin, Giorgia Mangili, William H Bradley, Ilan Bruchim, Kaiming Sun, Izabela A Malinowska, Yong Li, Divya Gupta, Bradley J Monk. N Engl J Med 2019
Times Cited: 338



Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh, Anke Reinacher-Schick, Giampaolo Tortora, Hana Algül, Eileen M O'Reilly, David McGuinness, Karen Y Cui, Katia Schlienger, Gershon Y Locker, Hedy L Kindler. N Engl J Med 2019
Times Cited: 487




List of shared articles



Times cited


Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Pierre-Marie Morice, Alexandra Leary, Charles Dolladille, Basile Chrétien, Laurent Poulain, Antonio González-Martín, Kathleen Moore, Eileen Mary O'Reilly, Isabelle Ray-Coquard, Joachim Alexandre. Lancet Haematol 2021
11


Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Talia Golan, Grainne M O'Kane, Robert E Denroche, Maria Raitses-Gurevich, Robert C Grant, Spring Holter, Yifan Wang, Amy Zhang, Gun Ho Jang, Chani Stossel,[...]. Gastroenterology 2021
7

Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards.
R Danesi, S Fogli, S Indraccolo, M Del Re, A P Dei Tos, L Leoncini, L Antonuzzo, L Bonanno, V Guarneri, A Pierini,[...]. ESMO Open 2021
1

Clinical considerations for the management of androgen indifferent prostate cancer.
Jacob E Berchuck, Paul V Viscuse, Himisha Beltran, Ana Aparicio. Prostate Cancer Prostatic Dis 2021
2


Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
0

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Fengping Shao, Yaoyun Duan, Yunhe Zhao, Yinguang Li, Jun Liu, Cai Zhang, Shanyang He. Aging (Albany NY) 2021
1

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials.
Roni Nitecki, Alexander Melamed, Allison A Gockley, Jessica Floyd, Kate J Krause, Robert L Coleman, Ursula A Matulonis, Sharon H Giordano, Karen H Lu, J Alejandro Rauh-Hain. Gynecol Oncol 2021
2

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R Grimes, Robert L Hollis, C Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson,[...]. Clin Cancer Res 2021
0

Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
Pierre-Marie Morice, Elodie Coquan, Louis-Bastien Weiswald, Bernard Lambert, Dominique Vaur, Laurent Poulain. Br J Cancer 2021
0

The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.
Michelle Shen, Shiqin Liu, Tanya Stoyanova. Am J Clin Exp Urol 2021
1

Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Francesco Schettini, Fabiola Giudici, Ottavia Bernocchi, Marianna Sirico, Silvia P Corona, Mario Giuliano, Mariavittoria Locci, Ida Paris, Giovanni Scambia, Sabino De Placido,[...]. Eur J Cancer 2021
3